Teprotumumab Improves Bulging, QOL in Thyroid Eye Disease

Source: Medscape News

Teprotumumab, a monoclonal antibody inhibitor of the IGF1 receptor, shows efficacy, including improvements in quality of life, in the treatment of moderate to severe thyroid eye disease, according to a report in Medscape.

“In the largest placebo-controlled evaluation thus far conducted in patients with active to severe thyroid eye disease, teprotumumab reduced proptosis, inflammation, and diplopia, resulting in marked quality of life improvements as compared with placebo at 24 weeks,” said co-author George J. Kahaly, MD, PhD, who presented the findings of a combined evaluation of phase 2 and 3 data at the 89th American Thyroid Association (ATA) Annual Meeting.

Read the full article.

Related Content